SCHEMBL5753256

SCHEMBL5753256

CN1CCN(c2ccc(N)c(-c3ccccc3C=O)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
GAA P10253 3/20 0.51
KDM4E B2RXH2 2/20 0.51
PTK2B Q14289 2/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
RECQL P46063 1/20 0.51
ADRA2C P18825 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HTR3A P46098 1/20 0.46
SIRT6 Q8N6T7 1/20 0.45
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43
KMT2A Q03164 2/20 0.43
GFER P55789 1/20 0.43
ESR2 Q92731 1/20 0.43
HTR6 P50406 2/20 0.41
NPC1 O15118 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3197069 0.82 MAPT (0.61) MAPTGAAKDM4EPTK2BMAPK1
SCHEMBL2913155 0.81 MAPT (0.56) MAPTGAAKDM4EPTK2BMAPK1
SCHEMBL2943140 0.80 MAPT (0.55) MAPTGAAKDM4EPTK2BMAPK1
SCHEMBL3685950 0.77 NPC1 (0.48) GAAKDM4EMAPK1ADRA2CALDH1A1
SCHEMBL3685781 0.74 ADORA2A (0.51) GAAALDH1A1HTR3AADORA2AADORA1
SCHEMBL6571919 0.72 ALDH1A1 (0.46) MAPTGAAKDM4EMAPK1HTT
SCHEMBL76547 0.71 GAA (0.73) MAPTGAAKDM4EPTK2BMAPK1
SCHEMBL29745032 0.71 GAA (0.73) MAPTGAAKDM4EPTK2BMAPK1
SCHEMBL2907550 0.71 GAA (0.59) MAPTGAAKDM4EPTK2BMAPK1
SCHEMBL21763659 0.71 HTR3A (0.56) GAAKDM4EADRA2CALDH1A1HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1157006-B1 PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2006-10-25 EP disclosed
US-6596773-B2 Central nervous system disorders HOFFMANN-LA ROCHE INC. 2003-07-22 US disclosed
US-20020111367-A1 Phenyl substituted pyridine and benzene derivatives BOS MICHAEL (CA) 2002-08-15 US disclosed
US-6407111-B1 SUBSTANCE P OR NEUROKININ 1 ANTAGONISTS; ANTIINFLAMMATORY, ANTIDEPRESSANT, ANTIARTHRITIC, AND ANTIASTHMATIC AGENTS; PARKINSON*S DISEASE, INFLAMMATORY BOWEL DISEASE, CENTRAL NERVOUS SYSTEM AND RHEUMATIC DISORDERS HOFFMANN-LA ROCHE INC. 2002-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111367-A1 Phenyl substituted pyridine and benzene derivatives BDKRB1, BAK1, PBK MAPT 4521/4885GAA 2255/4885KDM4E 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.